Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2024-08-08 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed unaudited financial results for the quarter ended June 30, 2024.
Regulatory Filings
2024-08-08 English
Please find the enclosed financial results for the quarter ended June 30, 2024.
Regulatory Filings
2024-08-08 English
Financial Result Updates
Regulatory Filings
2024-08-08 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs the stock exchanges about a final assessment order received by the company related to income tax for the assessment year 2020-21. The document includes details of the dispute and litigation but does not contain any financial statements or detailed financial analysis. It is a regulatory announcement about a legal proceeding and not a full audit report or annual report. The document length is short (2290 characters), and it serves as an official regulatory disclosure to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-27 English
Please find the enclosed letter of the Company in relation to the captioned subject for your reference.
Legal Proceedings Report Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about a final assessment order received from the Income Tax department. It includes details of a tax dispute and litigation, expected financial implications, and the intention to challenge the order before the Income-tax Appellate Tribunal. The document is addressed to stock exchanges and is a regulatory announcement about a legal proceeding rather than a full legal proceedings report or financial report. It does not contain financial statements or detailed management discussion but is a compliance disclosure about a legal matter. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is short and it is not an announcement of a report publication but a substantive disclosure of a legal matter.
2024-07-27 English
Board Meeting — ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Board Meeting to be held on 08-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Comp…
Regulatory Filings
2024-07-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.